SCHEMBL28236646

SCHEMBL28236646

C[C@@H](c1ccc(F)c(F)c1)c1ccc2ncncc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.45
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
MET P08581 1/20 0.39
PDE1A P54750 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE1C Q14123 1/20 0.39
PDE3A Q14432 1/20 0.39
PDE11A Q9HCR9 1/20 0.39
PDE10A Q9Y233 1/20 0.39
RPS6KB1 P23443 1/20 0.38
FGFR4 P22455 1/20 0.37
BRAF P15056 2/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28236647 1.00 EGFR (0.45) EGFRPIK3CDPIK3CAMETPDE1A
SCHEMBL2611054 0.79 EGFR (0.55) EGFRPIK3CDPIK3CAPDE10AFGFR4
SCHEMBL30804805 0.79 EGFR (0.55) EGFRPIK3CDPIK3CAFGFR4BRAF
SCHEMBL23335615 0.76 EGFR (0.51) EGFRPIK3CDPIK3CAMETFGFR4
SCHEMBL27666530 0.76 EGFR (0.51) EGFRPIK3CDPIK3CAFGFR4TDO2
SCHEMBL2619213 0.75 EGFR (0.50) EGFRPIK3CDPIK3CAFGFR4BRAF
SCHEMBL16105634 0.75 CES2 (0.44) CYP1A2PDPK1AKR1C3AKR1C2
SCHEMBL21648655 0.74 EGFR (0.49) EGFRPIK3CDPIK3CAFGFR4BRAF
SCHEMBL20032418 0.72 EGFR (0.50) EGFRPIK3CDPIK3CAMETFGFR4
SCHEMBL28128185 0.72 EGFR (0.46) EGFRFGFR4USP2CYP1A2TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473472-A 2-aminoquinazoline derivatives as P70S6 kinase inhibitors 圣提内尔肿瘤学有限公司 2018-08-31 CN disclosed